Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | QPCT | Q16769 | 1/20 | 0.44 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2603250 | 0.87 | CYP2D6 (0.50) | CYP2D6HRH3 | |
| SCHEMBL1641207 | 0.72 | QPCT (0.62) | CYP2D6HRH3QPCTQPCTLKMT2A | |
| SCHEMBL14375261 | 0.71 | HRH3 (0.56) | HRH3ALDH1A1 | |
| SCHEMBL14028152 | 0.71 | POLB (0.73) | NPC1RAB9AKMT2AALDH1A1LMNA | |
| SCHEMBL1527998 | 0.70 | TBXAS1 (0.72) | CYP2D6HRH3QPCTQPCTLALDH1A1 | |
| SCHEMBL13779951 | 0.70 | ALDH1A1 (0.51) | HRH3QPCTQPCTLKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL1371691 | 0.69 | TBXAS1 (0.75) | CYP2D6HRH3QPCTQPCTLALDH1A1 | |
| SCHEMBL9954227 | 0.69 | HRH4 (0.57) | CYP2D6HRH3QPCTQPCTLKMT2A | |
| SCHEMBL17040362 | 0.69 | TBXAS1 (0.56) | CYP2D6HRH3QPCTQPCTLALDH1A1 | |
| SCHEMBL13504053 | 0.69 | SMN1; SMN2 (0.69) | NPC1RAB9AKMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | THE UNIVERSITY OF EDINBURGH (GB) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095046-A1 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders | HSD11B1, HSD11B2, HSD3B1 | CYP2D6 955/4885NPC1 155/4885HRH3 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.